Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0040425 (tonsillitis)
 1,594 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Forty-two pediatric patients were treated with ceftazidime ( CAZ ) in the doses ranging from 45.6 to 120 mg/kg/day for 2 to 10 days, and the clinical efficacy and side effects were evaluated. Among the 37 children with bacterial infections including pneumonia, bronchitis, tonsillitis, croup, cervical lymphadenitis, abdominal abscess and urinary tract infections, the results were excellent in 22, good in 12, fair in 2, and poor in 1 patient with pneumonia. Out of the 42 patients, 5 cases showed eosinophilia, but no clinical sign such as rash, fever or diarrhea, attributable to CAZ was observed during the study. The serum concentrations of CAZ in 4 patients ranged from 60.8 to 71.0 micrograms/ml (mean 66.1 micrograms/ml) at 30 minutes and from 0.5 to 1.2 micrograms/ml (mean 0.8 micrograms/ml) at 8 hours after 20 mg/kg intravenous bolus injection of the antibiotic. The mean serum half-life was 1.42 hours (85 minutes). Patients with impairment of renal function were excluded from this study.
 ...
PMID:[Clinical and pharmacokinetic evaluation of ceftazidime in children]. 637 45

Ceftazidime ( CAZ ), a new injectable cephem antibiotic, was used for treatment of infections in children, and the following results were obtained. After an intravenous injection of CAZ at a dose of 20 mg/kg, the mean blood levels in 2 patients were 41.5 micrograms/ml at 30 minutes, 18.1 micrograms/ml at 2 hours and 2.55 micrograms/ml at 6 hours, with the half-life (T 1/2) of 1.37 hours. In a 22-day-old baby with meningitis given CAZ intravenously at a dose of 43.5 mg/kg, the blood levels were 100 micrograms/ml at 30 minutes, 68 micrograms/ml at 2 hours and 25 micrograms/ml at 6 hours, with the half-life (T 1/2) of 2.96 hours. After intravenous administration of CAZ in doses ranging from 35.7 to 50 mg/kg, CSF concentrations ranged from N.D. to 6.3 micrograms/ml in 3 patients with purulent meningitis, although 19 micrograms/ml at 1 hour and 13 micrograms/ml at 2 hours in 1 patient after intravenous administration of 46.7 mg/kg. In patient with mumps meningitis, CSF concentrations were undetectable after intravenous administration of 35.7 mg/kg. Seventeen patients (each 1 patient with lymphadenitis, tonsillitis and septicemia, each 2 patients with pneumonia, bronchiectatic bronchitis, pyothorax and purulent meningitis, each 3 patients with pyelonephritis and enteritis) were treated with CAZ intravenously, at the daily doses of 178.2 mg/kg and 200 mg/kg in 4 divided doses in patients with meningitis and 44.1 to 103.4 mg/kg in 3 divided doses in patients with other infections (two of them were given by intravenous drip infusion for 30 minutes). The clinical responses were excellent or good in all the patients except for 1 case of Salmonella enteritis (poor) and 1 case of Campylobacter enteritis (poor). The efficacy rate was 88.2%. It was noteworthy that the clinical response was excellent in 1 case of septicemia with P. aeruginosa with leukemic stage of malignant lymphoma and in 2 cases of purulent meningitis. As side effects, fever, eruption, leukocytopenia, elevation in GOT and positive CRP considered to be allergic, were observed on day 16 of administration in 1 case of pyothorax. These symptoms disappeared by discontinuance of administration. In addition, there were elevation in GOT and GPT in 2 cases and elevation in GOT in 2 cases and elevation in GPT in 1 case; they were all mild or transient, and there was nothing to be worried about.(ABSTRACT TRUNCATED AT 400 WORDS)
 ...
PMID:[Clinical evaluation of ceftazidime in paediatrics]. 637 60

Infectious morbidity in respect to 23 nosological forms was studied in 958 children with known blood groups and Rh factors during the first 7 years of their life. The absence of statistically significant differences in morbidity rates in children with different age groups was revealed in respect to 16 nosological forms. Significant differences in morbidity rates in children with different blood groups were revealed in respect to parotitis, rubella, scarlet fever, E. coli infections, bronchitis and pneumonia; similar differences linked with Rh factor were observed only in cases of measles, rubella and tonsillitis.
 ...
PMID:[Hereditary blood factors and infectious diseases in children in the 1st 7 years of life]. 640 58

Clinical studies on cefoperazone (CPZ), a new cephalosporin, were carried out at our department. Seventeen children wih the following bacterial infections were treated with CPZ; pneumonia (7), bronchitis (6), tonsillitis (1), sepsis (2) and purulent meningitis (1). The dosage was 56 approximately 182 mg/kg/day, divided into 4 doses, and given intravenous injection. The duration of administration was from 4 to 15 days. Clinical results were excellent in 3 cases, good in 9 cases, moderate in 3 cases, poor in 1 case and uncertain in 1 case. The overall efficacy rate was 75.0%. No side effects were observed.
 ...
PMID:[Clinical examination of cefoperazone in pediatrics (author's transl)]. 645 43

Pharmacokinetic and clinical studies of ampicillin suppository (KS-R1) was performed in children. The results were as follows. Peak serum level of ampicillin (ABPC) after single administration of KS-R1 contains 125 mg or 250 mg of ABPC in potency was 6.03 micrograms/ml after 15 minutes and 5.78 micrograms/ml after 30 minutes, respectively. The half-life was 30.4 minutes and 30.9 minutes, respectively. Urinary excretion rate was 34.2-70.1% within 6 hours. A clinical study of KS-R1 was performed in 40 patients including purulent tonsillitis (10 cases), pharyngitis (9 cases), bronchitis (6 cases), bronchopneumonia (2 cases), scarlet fever (8 cases), otitis media (1 case) and urinary tract infection (4 cases). The clinical effects, excellent and good responses, were showed in 37 cases (efficacy rate; 92.5%). No side effects and abnormal laboratory findings were observed.
 ...
PMID:[Experimental and clinical studies of an ampicillin suppository (KS-R1) in pediatrics]. 665 12

The basic and clinical studies of ampicillin suppository (KS-R1) in pediatric infections were carried out, and the following results were obtained: For study of absorption and excretion of KS-R1, a single dose of 250 mg of KS-R1 was administered to 3 cases. The mean serum levels were obtained 4.10 +/- 1.55 micrograms/ml at 30 minutes, and 1.52 +/- 0.25 micrograms/ml, 0.38 +/- 0.04 micrograms/ml at 1 and 2 hours after rectal administration, respectively. The serum levels were not detectable after 4 hours in all cases. The half lives were 0.39, 0.54 hour and 0.44 hour, respectively. The mean urinary excretion rate to 6 hours was 14.8%. Clinical efficacy was evaluated in 17 cases with tonsillitis (15 cases), bronchitis (1 case) and scarlet fever (1 case). Good responses were obtained in 15 of 17 cases (88.2%). Bacteriological response in the form of eradication was noted in 4 of 5 cases. Side effects were examined with all of the 19 cases, and eosinophilia was observed in 1 case.
 ...
PMID:[Experimental and clinical evaluation of an ampicillin suppository (KS-R1)]. 665 15

Fundamental and clinical studies on cefpiramide (CPM), a new semisynthetic cephalosporin were performed and the following results were obtained. Antibacterial activity The antibacterial activity of CPM was investigated in comparison with those of CTT, CPZ, CEZ, LMOX and CFS. Against clinical isolates of S. aureus, CPM was superior to CTT and LMOX, but almost similar to CPZ and inferior to CEZ. Against E. coli, K. pneumoniae, P. mirabilis and S. marcescens, CPM showed the activity almost similar to that of CEZ, but inferior to those of the others. On the contrary, the activity of CPM against P. aeruginosa was satisfactory and was superior to those of CTT, CPZ and LMOX, but slightly inferior to that of CFS. Blood level and urinary recovery Twenty mg/kg of CPM was given intravenously at one shot to 3 patients. The mean serum levels of CPM were 116.9 micrograms/ml at 30 minutes, 90.5 micrograms/ml at 1 hour, 71.1 micrograms/ml at 2 hours, 55.8 micrograms/ml at 4 hours, 24.9 micrograms/ml at 6 hours, 19.3 micrograms/ml at 9 hours and 12.1 micrograms/ml at 12 hours after administration, respectively. The mean half-life was very long and the value was 3.85 hours. The urinary recovery rates in 2 cases were 18.31 and 21.47% respectively up to 12 hours after administration. Clinical results and side effects CPM was given intravenously to 30 diseases including 11 cases of bronchopneumonia, 3 cases of bronchopneumonia and pleurisy, 2 cases of bronchitis, 4 cases of purulent tonsillitis, 5 cases of pyelonephritis and each one case of pyothorax, parotitis, cellulitis, otitis media and salmonellosis. CPM was effective in 29 out of 30 cases, and the effective rate was 96.7%. As side effects, 2 cases of fever and 1 case of cough were observed, but no abnormality in clinical laboratory findings was observed.
 ...
PMID:[Experimental and clinical evaluation of cefpiramide in pediatrics]. 665 42

Antibiotic therapy, in contrast to other drug treatments, is aimed at the etiology of a given disease state. The main basis of antimicrobial chemotherapy is thus identification of the causative pathogen and documentation of its susceptibility to the least toxic antibiotic. However, these requirements are frequently impossible to meet in everyday management of infections. In many situations, therefore, decision-making in antimicrobial chemotherapy must be based on a "best-guess" diagnosis regarding the causative pathogen and its susceptibility to the antibiotic. The process of decision-making in antimicrobial chemotherapy for the single most frequent infections encountered in outpatients is discussed, and the pertinent antimicrobial treatment for these infections (pharyngo-tonsillitis, otitis media, sinusitis, bronchitis and urinary tract infections) is outlined.
 ...
PMID:[Microbiologic principles of antibiotic therapy]. 672 16

The newly developed cefadroxil (CDX) dry syrup in a mean daily dose of 32.9 mg/kg t.i.d. or q.i.d. was administered to children for a period of 8 days on the average; viz. a total of 64 cases consisting of 39 cases of tonsillitis, 2 of tonsillitis complicated with otitis media, 1 of bronchitis, 1 of pneumonia, 14 of scarlet fever, and 7 of urinary tract infections; and its clinical and bacteriological effects, and adverse reactions were examined, leading to the following results. 1. The clinical effects were "good" or "excellent" in any of 39 cases of tonsillitis, 2 of tonsillitis complicated with otitis media, 1 of pneumonia, 14 of scarlet fever, and 7 of urinary tract infections, and "fair" only in a case of bronchitis, showing the high efficacy of 98.4%. 2. The clinical effects by daily dose were compared only in the great cases of tonsillitis between the 2 daily dose groups of 30 mg/kg or below and 31 to 40 mg/kg, and both groups showed "good" or "excellent" results, but the latter group revealed that the excellent rate was greater by 20.8% than that of the former group. 3. The frequency of daily administration was 3 times or 4 times and the cases of 4 times administration were few in any disease. In comparison of clinical effects between the 3 times group and the 4 times group in the whole cases, no significant difference was observed between both groups but it is desirable to make the 4 times administration in view of the pharmacokinetics. 4. The bacteriological effects could be judged in 15 cases, namely bacteria were eradicated in 14 cases and unchanged in 1 case, showing a good result of the eradication rate as 93.3%. 5. No adverse reaction was observed and the laboratory test values showed eosinophilia in 7 cases (15.9%) and abnormal elevations of GPT in 1 case (4.5%), of GOT and GPT in 2 case (9.1%), of LDH in 1 case (4.8%) and of BUN in 1 case (4.8%), but 4 of the 7 cases with eosinophilia seemed attributable to underlying diseases or objective diseases. From the above it can be said that this preparation is a useful drug in mild bacterial diseases.
 ...
PMID:[Clinical studies on cefadroxil in the field of pediatrics]. 684 30

T-1982 (cefbuperazone) was given at a daily dose of 42-80 mg/kg to 7 children with bacterial infections; 3 with bacterial intestinitis, 1 with bronchitis, 1 with tonsillitis and 2 with urinary tract infections. Clinical effectiveness was obtained in 6 cases, and the rate was 85.7%. Bacteriological responses were "disappeared" in 4 cases, "decreased" in 1 case and "unknown" in 2 cases. No noticeable side effects were observed except elevation of eosinophil in 1 case.
 ...
PMID:[Clinical efficacy of T-1982 (cefbuperazone) for infections of children]. 687 77


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>